ASLAN Pharmaceuticals: ASLAN Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023

ASLAN Pharmaceuticals Limited reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 12 million. Net loss was USD 44.22 million compared to USD 51.38 million a year ago. Basic loss per share from continuing operations was USD 2.75 compared to USD 3.75 a year ago. Diluted loss per share from continuing operations was USD 2.75 compared to USD 3.75 a year ago.